Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27839938 | 0.87 | LMNA (0.42) | LMNAKDM4ECYP3A4ACHEABCB11 | |
| SCHEMBL6303758 | 0.86 | LMNA (0.44) | LMNAKDM4ECYP3A4ACHEABCB11 | |
| SCHEMBL31261701 | 0.84 | ELANE (0.49) | ELANE | |
| SCHEMBL27839934 | 0.83 | LMNA (0.44) | LMNAKDM4ECYP3A4ACHEABCB11 | |
| SCHEMBL5861768 | 0.81 | LMNA (0.49) | LMNAKDM4ECYP3A4ACHEALDH1A1 | |
| SCHEMBL7660763 | 0.81 | KDM4E (0.53) | LMNAKDM4ECYP3A4ACHEALDH1A1 | |
| SCHEMBL2294115 | 0.81 | LMNA (0.46) | LMNAKDM4ECYP3A4ACHEMAPT | |
| SCHEMBL16857133 | 0.80 | HTR2A (0.43) | LMNAKDM4ECYP3A4ACHEABCB11 | |
| SCHEMBL473532 | 0.80 | LMNA (0.52) | LMNAKDM4ECYP3A4ACHEABCB11 | |
| SCHEMBL14122683 | 0.79 | TDP1 (0.53) | KDM4EALDH1A1PKMGAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108368090-B | Compounds as immunomodulators | 百时美施贵宝公司 | 2022-04-12 | — | — | CN | disclosed |
| US-10745382-B2 | Compounds useful as immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-18 | — | — | US | disclosed |
| EP-3362443-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2018-08-22 | — | — | EP | disclosed |
| CN-108368090-A | Compounds as Immunomodulators | 百时美施贵宝公司 | 2018-08-03 | — | — | CN | disclosed |
| US-20170107202-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-20 | — | — | US | disclosed |
| WO-2017066227-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-20 | — | — | WO | disclosed |
| US-20110159019-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110159019-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110159019-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-30 | — | — | US | disclosed |
| EP-2325175-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2011-05-25 | — | — | EP | disclosed |
| WO-2009005672-A1 | ANTIDIABETIC AZAINDOLES AND DIAZAINDOLES | MERCK & CO., INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009005672-A1 | ANTIDIABETIC AZAINDOLES AND DIAZAINDOLES | MERCK & CO., INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745382-B2 | Compounds useful as immunomodulators | CD74, HLA-DRB1, CD47 | LMNA 4791/4885KDM4E 4249/4885CYP3A4 3478/4885 |
| US-20110159019-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | PRKCZ, DCLK1, AAK1 | LMNA 4431/4885KDM4E 1012/4885CYP3A4 2474/4885 |
| US-20170107202-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | CD74, HLA-DRB1, CD47 | LMNA 4791/4885KDM4E 4249/4885CYP3A4 3478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.